ZA200304387B - Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus. - Google Patents

Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus. Download PDF

Info

Publication number: ZA200304387B
Authority: ZA; South Africa
Prior art keywords: hiv; virus; gene; vaccine formulation; recombinant
Prior art date: 2001-02-28

Application number

ZA200304387A

Other languages

English (en)

Inventor

Enrique Iglesias Perez

Carlos A Duarte Cano

Dania M Vazquez Blomquist

Original Assignee

Ct Ingenieria Genetica Biotech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-28

Filing date

2003-06-04

Publication date

2004-08-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40091626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200304387(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-06-04 Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech

2004-08-11 Publication of ZA200304387B publication Critical patent/ZA200304387B/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Immunology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

ZA200304387A 2001-02-28 2003-06-04 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus. ZA200304387B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CU20010057A CU23235A1 (es)	2001-02-28	2001-02-28	POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA

Publications (1)

Publication Number	Publication Date
ZA200304387B true ZA200304387B (en)	2004-08-11

Family

ID=40091626

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200304387A ZA200304387B (en)	2001-02-28	2003-06-04	Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus.

Country Status (16)

Country	Link
US (2)	US7318927B2 (pt)
EP (1)	EP1371730B1 (pt)
JP (1)	JP4125128B2 (pt)
KR (1)	KR100920141B1 (pt)
CN (1)	CN1526018B (pt)
AR (1)	AR032871A1 (pt)
AT (1)	ATE435916T1 (pt)
AU (1)	AU2002237195B2 (pt)
BR (2)	BRPI0206823B1 (pt)
CA (1)	CA2430702C (pt)
CU (1)	CU23235A1 (pt)
DE (1)	DE60232862D1 (pt)
ES (1)	ES2329768T3 (pt)
RU (1)	RU2302461C2 (pt)
WO (1)	WO2002068654A2 (pt)
ZA (1)	ZA200304387B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9711957D0 (en)	1997-06-09	1997-08-06	Isis Innovation	Methods and reagents for vaccination
GB0118532D0 (en)	2001-07-30	2001-09-19	Isis Innovation	Materials and methods relating to improved vaccination strategies
CN101024842A (zh)	2001-11-07	2007-08-29	曼康公司	编码靶相关抗原表位的表达载体及其设计方法
AU2002347317B2 (en)	2001-11-30	2008-06-26	Isis Innovation Limited	Vaccine
GB0225786D0 (en) *	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
GB0225788D0 (en)	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
AU2004291024B2 (en) *	2003-02-20	2009-09-17	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Novel insertion sites in pox vectors
GB0417494D0 (en) *	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
US20080124355A1 (en)	2006-09-22	2008-05-29	David Gordon Bermudes	Live bacterial vaccines for viral infection prophylaxis or treatment
EP2620446A1 (en)	2012-01-27	2013-07-31	Laboratorios Del Dr. Esteve, S.A.	Immunogens for HIV vaccination
FR2987836A1 (fr) *	2012-03-09	2013-09-13	Biomerieux Sa	Peptides d'interference et procede de detection de microorganismes
US20150238580A1 (en) *	2012-09-28	2015-08-27	Ellis Kline	Glycosidase regimen for treatment of infectious disease
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
CN114340661A (zh) *	2019-07-02	2022-04-12	磨石生物公司	Hiv抗原和mhc复合物
BR112022009421A2 (pt)	2019-11-14	2022-10-25	Aelix Therapeutics S L	Regimes de dosagem para vacinas
CN112852749A (zh) *	2021-03-27	2021-05-28	哈尔滨元亨生物药业有限公司	高效分泌犬细小病毒单克隆抗体杂交瘤细胞株c68及利用生物反应器对其进行生产的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5505941A (en) *	1981-12-24	1996-04-09	Health Research, Inc.	Recombinant avipox virus and method to induce an immune response
US5174993A (en) *	1981-12-24	1992-12-29	Health Research Inc.	Recombinant avipox virus and immunological use thereof
GB8918200D0 (en) *	1989-08-09	1989-09-20	Medical Res Council	The peptide fragments of hiv
US7255862B1 (en)	1996-11-14	2007-08-14	Connaught Technology Corporation	ALVAC/FIV constructs

2001
- 2001-02-28 CU CU20010057A patent/CU23235A1/es unknown
2002
- 2002-02-22 ES ES02703488T patent/ES2329768T3/es not_active Expired - Lifetime
- 2002-02-22 BR BRPI0206823-0A patent/BRPI0206823B1/pt unknown
- 2002-02-22 JP JP2002568748A patent/JP4125128B2/ja not_active Expired - Fee Related
- 2002-02-22 US US10/469,256 patent/US7318927B2/en not_active Expired - Fee Related
- 2002-02-22 RU RU2003128991/13A patent/RU2302461C2/ru not_active IP Right Cessation
- 2002-02-22 KR KR1020037009273A patent/KR100920141B1/ko active IP Right Grant
- 2002-02-22 DE DE60232862T patent/DE60232862D1/de not_active Expired - Lifetime
- 2002-02-22 BR BR0206823-0A patent/BR0206823A/pt not_active IP Right Cessation
- 2002-02-22 AU AU2002237195A patent/AU2002237195B2/en not_active Ceased
- 2002-02-22 AT AT02703488T patent/ATE435916T1/de not_active IP Right Cessation
- 2002-02-22 WO PCT/CU2002/000001 patent/WO2002068654A2/es active Application Filing
- 2002-02-22 CN CN028034139A patent/CN1526018B/zh not_active Expired - Fee Related
- 2002-02-22 EP EP02703488A patent/EP1371730B1/en not_active Expired - Lifetime
- 2002-02-22 CA CA2430702A patent/CA2430702C/en not_active Expired - Fee Related
- 2002-02-27 AR ARP020100686A patent/AR032871A1/es not_active Application Discontinuation
2003
- 2003-06-04 ZA ZA200304387A patent/ZA200304387B/en unknown
2006
- 2006-07-14 US US11/486,535 patent/US20080280354A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60232862D1 (de)	2009-08-20
US20040073008A1 (en)	2004-04-15
RU2302461C2 (ru)	2007-07-10
ATE435916T1 (de)	2009-07-15
AU2002237195B2 (en)	2007-01-04
US20080280354A1 (en)	2008-11-13
AR032871A1 (es)	2003-11-26
WO2002068654A3 (es)	2003-03-13
BRPI0206823B1 (pt)	2018-08-14
KR20030079946A (ko)	2003-10-10
JP4125128B2 (ja)	2008-07-30
CA2430702C (en)	2013-07-09
KR100920141B1 (ko)	2009-10-08
BR0206823A (pt)	2004-02-25
CN1526018A (zh)	2004-09-01
CU23235A1 (es)	2007-09-26
CA2430702A1 (en)	2002-09-06
ES2329768T3 (es)	2009-12-01
US7318927B2 (en)	2008-01-15
RU2003128991A (ru)	2005-01-20
JP2004518443A (ja)	2004-06-24
EP1371730B1 (en)	2009-07-08
CN1526018B (zh)	2013-04-03
EP1371730A2 (en)	2003-12-17
WO2002068654A2 (es)	2002-09-06

Publication	Publication Date	Title
US20080280354A1 (en)	2008-11-13	Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
Earl et al.	2002	Comparison of vaccine strategies using recombinant env–gag–pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model
Lu et al.	1996	Simian immunodeficiency virus DNA vaccine trial in macaques
Davis et al.	2000	Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
EP0969862B1 (en)	2006-10-18	Synthetic hiv gag genes
Pal et al.	2006	Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype
US7993651B2 (en)	2011-08-09	Chimeric human immunodeficiency virus (HIV) immunogens comprising GAG P24-P17 fused to multiple cytotoxic T lymphocyte (CTL) epitopes
AU712431B2 (en)	1999-11-04	Recombinant attenuated ALVAC canarypox expression vectors containing heterologous DNA segments encoding lentiviral gene products
BG64711B1 (bg)	2005-12-30	Смес от рекомбинантни вектори на ваксина като роlyеnv ваксини за нiv
CZ266798A3 (cs)	1999-03-17	Syntetický polynukleotid obsahující DNA sekvence kódující HIV proteiny
US20090227658A1 (en)	2009-09-10	Methods and compositions for immunization against hiv
Smith	2002	HIV vaccine development in the nonhuman primate model of AIDS
US20080306244A1 (en)	2008-12-11	Renta: an HIV immunogen and uses thereof
Radaelli et al.	2007	Prime-boost immunization with DNA, recombinant fowlpox virus and VLPSHIV elicit both neutralizing antibodies and IFNγ-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells
Blomquist et al.	2002	Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide
Wild et al.	2009	Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model
Mossman et al.	1999	Immunization against SIVmne in macaques using multigenic DNA vaccines
Young et al.	2006	Elicitation of immunity to HIV type 1 Gag is determined by Gag structure
JP2006503800A (ja)	2006-02-02	Ｈｉｖに対する強化された免疫応答を誘導する方法
Singh et al.	2005	HIV vaccine development
Vázquez-Blomquist et al.	2003	The HIV-1 chimeric protein CR3 expressed by poxviral vectors induces a diverse CD8+ T cell response in mice and is antigenic for PBMCs from HIV+ patients
Norley	2010	AIDS Vaccines: the Unfolding Story
Clade	2009	Comparison of Human and Rhesus
VázquezBlomquist et al.	0	Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus
McGettigan Jr	2002	Cellular immune responses against HIV-1 proteins expressed by a highly attenuated rabies-virus-based vaccine vector